Enlivex Ltd. (ENLV)
0.2775
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 12:16
Enlivex Enterprise Value : 16.58M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 16.58M |
| October 07, 2026 | 17.07M |
| October 06, 2026 | 17.64M |
| October 05, 2026 | 18.01M |
| October 02, 2026 | 18.43M |
| October 01, 2026 | 19.03M |
| September 30, 2026 | 20.38M |
| September 29, 2026 | 19.99M |
| September 28, 2026 | 20.56M |
| September 25, 2026 | 21.97M |
| September 24, 2026 | 22.11M |
| September 23, 2026 | 22.69M |
| September 22, 2026 | 22.79M |
| September 21, 2026 | 23.57M |
| September 18, 2026 | 25.49M |
| September 17, 2026 | 24.15M |
| September 16, 2026 | 25.57M |
| September 15, 2026 | 26.77M |
| September 14, 2026 | 26.46M |
| September 11, 2026 | 28.06M |
| September 10, 2026 | 28.42M |
| September 09, 2026 | 29.42M |
| September 08, 2026 | 30.60M |
| September 04, 2026 | 30.43M |
| September 03, 2026 | 31.44M |
| Date | Value |
|---|---|
| September 02, 2026 | 32.95M |
| September 01, 2026 | 33.46M |
| August 31, 2026 | 33.46M |
| August 28, 2026 | 34.64M |
| August 27, 2026 | 36.74M |
| August 26, 2026 | 37.41M |
| August 25, 2026 | 37.50M |
| August 24, 2026 | 37.33M |
| August 21, 2026 | 36.66M |
| August 20, 2026 | 37.16M |
| August 19, 2026 | 41.03M |
| August 18, 2026 | 37.50M |
| August 17, 2026 | 38.51M |
| August 14, 2026 | 38.51M |
| August 13, 2026 | 40.36M |
| August 12, 2026 | 42.88M |
| August 11, 2026 | 44.23M |
| August 10, 2026 | 45.75M |
| August 07, 2026 | 46.92M |
| August 06, 2026 | 45.24M |
| August 05, 2026 | 48.61M |
| August 04, 2026 | 47.43M |
| August 03, 2026 | 48.44M |
| July 31, 2026 | 47.09M |
| July 30, 2026 | 44.74M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Polyrizon Ltd. | -- |
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 11.43M |
| Summit Therapeutics, Inc. | 12.95B |
| PeptiDream Inc. | 844.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.892B |
| Total Expenses (Quarterly) | -1.892B |
| EPS Diluted (Quarterly) | 97.84 |
| Earnings Yield | 173.7K% |
| Normalized Earnings Yield | 13395.42 |